O112. A novel fusogenic herpes simplex virus mutant for oncolytic virotherapy of oral squamous cell carcinoma

2009 ◽  
Vol 3 (1) ◽  
pp. 93-94
Author(s):  
Y. Yura ◽  
H. Takaoka ◽  
F. Ogawa ◽  
M. Shintani ◽  
S. Iwai
Keyword(s):  
Squamous Cell Carcinoma ◽  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Oncolytic Virotherapy ◽  
Virus Mutant ◽  
Simplex Virus

DETECTION OF RNA COMPLEMENTARY TO HERPES SIMPLEX VIRUS IN HUMAN ORAL SQUAMOUS CELL CARCINOMA

The Lancet ◽  
1983 ◽  
Vol 322 (8353) ◽  
pp. 766-768 ◽  
Author(s):  
R.P. Eglin ◽  
C. Scully ◽  
T. Lehner ◽  
P. Ward-Booth ◽  
I.A. Mcgregor
Keyword(s):  
Squamous Cell Carcinoma ◽  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Simplex Virus

scholarly journals A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma

2011 ◽  
Vol 8 (1) ◽  
pp. 294 ◽  
Author(s):  
Hiroo Takaoka ◽  
Gen Takahashi ◽  
Fumi Ogawa ◽  
Tomoaki Imai ◽  
Soichi Iwai ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Oncolytic Virotherapy ◽  
Simplex Virus

Human papillomavirus and herpes simplex virus in vulvar squamous cell carcinoma in situ

1988 ◽  
Vol 158 (4) ◽  
pp. 862-869 ◽  
Author(s):  
Raymond H. Kaufman ◽  
Jacob Bornstein ◽  
Ervin Adam ◽  
Joyce Burek ◽  
Barbara Tessin ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Papillomavirus ◽  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Carcinoma In Situ ◽  
Vulvar Squamous Cell Carcinoma ◽  
Simplex Virus

A comparative review of the potential role of adenovirus and Herpes Simplex Virus in the treatment of advanced squamous cell carcinoma of the head and neck

2009 ◽  
Vol 8 (3) ◽  
pp. 147-155
Author(s):  
Stuart McCaighy
Keyword(s):  
Immune Response ◽  
Squamous Cell Carcinoma ◽  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Phase Iii ◽  
Advanced Squamous Cell Carcinoma ◽  
Simplex Virus

AbstractThe unsatisfactory outcome of patients who receive intensive multimodality treatment for advanced squamous cell carcinoma of the head and neck (SCCHN) has motivated investigators to seek novel treatments to improve survival. Advances in molecular biology has led to the development of cancer gene therapy (CGT) and revived interest in viral vectors as a mechanism. SCCHN is an ideal model for CGT as disease remains locoregional and is amenable to injection of viruses. Adenovirus and Herpes Simplex Virus Type-1 (HSV) are the most studied Oncolytic Viruses (OVs). Both viruses have been shown to select and replicate in tumour cells and demonstrate anti-tumour effect in laboratory studies and clinical trials. Toxicity from OVs is minor and manageable. Different adenoviral mutants have been investigated with mixed responses. One vector, H101, has now been licensed after showing significant tumour regression in conjunction with chemotherapy. HSV has a larger capacity to carry genetic material and with the addition of the granulocyte–macrophage colony–stimulating factor, has the potential to stimulate an immune response systemically and at the site of disease. OVs are limited by the distribution of virus beyond injection site and by pre-existing or rapidly established immune response. Phase III studies are required.

Sign in / Sign up

Export Citation Format

Share Document